Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings ... off on the lowest dose – or the starter dose – then work ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk recently reported data from a phase 1b/2a clinical trial for the subcutaneous formulation of amycretin. The study enrolled 125 overweight or obese patients, with some receiving ...

Novo Nordisk shares rose Wednesday after fourth ... dose – or the starter dose – then work their way up to stronger formulations so their bodies can get used to the drug.